11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Attenuates the Adverse Effects of Glucocorticoids on Dermal Papilla Cells

    January 2017 in “ Yonsei Medical Journal
    Sang Eun Lee, Eun Young Lee, Sang Jin Kang, Seung Hun Lee
    New to Vascular Endothelial Growth Factor? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This study found that inhibiting 11β-HSD1 can partially reverse the negative impact of glucocorticoids on dermal papilla cells in human scalps, suggesting potential for treating stress-related hair loss.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study from 2017 explored the expression of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) in human dermal papilla cells (DPCs) and its potential as a target to counteract the negative effects of glucocorticoids on hair growth. Glucocorticoids, which are known to inhibit hair growth, increase the expression of 11β-HSD1 in DPCs. The researchers discovered that treatment with glucocorticoids decreased cell proliferation and the expression of hair growth markers such as Wnt5a, alkaline phosphatase (ALP), and vascular endothelial growth factor (VEGF) in DPCs. However, using a selective 11β-HSD1 inhibitor significantly reduced these adverse effects, suggesting that such inhibitors could be a therapeutic option for stress-related hair loss. The number of participants or samples used in the study was not mentioned in the summary.
    Discuss this study in the Community →

    Research cited in this study

    14 / 14 results